Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices

Interactive Practice Guide

Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies?  Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status should be determined for all patients. To optimize treatment, clinicians must not only have current knowledge of current biomarker testing and treatment selection, but also the operational frameworks to effectively translate this latest evidence into practice. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensure your patients are benefitting from the latest advancements in care.

Faculty: Manish A. Shah, MD, FASCO, Geoffrey Ku, MD

Release Date: June 28, 2024

Expiration Date: June 28, 2025